Jay Olson
Stock Analyst at Oppenheimer
(3.99)
# 604
Out of 5,008 analysts
244
Total ratings
44.39%
Success rate
13.78%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMRX Immuneering | Maintains: Outperform | $21 → $30 | $6.40 | +368.75% | 3 | Sep 25, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $44 | $8.36 | +426.63% | 4 | Aug 11, 2025 | |
| MNMD Mind Medicine (MindMed) | Reinstates: Outperform | $25 | $12.62 | +98.10% | 1 | Aug 4, 2025 | |
| ATAI Atai Life Sciences | Initiates: Outperform | $14 | $5.54 | +152.71% | 1 | Jul 29, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $97 → $115 | $54.43 | +111.28% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $19 → $22 | $21.51 | +2.30% | 15 | Jun 26, 2025 | |
| PRTA Prothena Corporation | Downgrades: Perform | n/a | $10.38 | - | 15 | May 27, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Outperform | $65 | $39.72 | +63.65% | 1 | May 21, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $80 → $65 | $2.36 | +2,660.08% | 5 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Maintains: Outperform | $15 → $13 | $2.66 | +388.72% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $75 | $49.20 | +52.44% | 9 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $90 | $58.04 | +55.07% | 6 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $42 | $15.96 | +163.16% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $41 → $33 | $39.14 | -15.69% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $40 | $25.18 | +58.86% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $3.01 | +564.45% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $7.48 | +301.07% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $8.31 | +140.67% | 2 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $255 | $151.61 | +68.19% | 25 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $86.51 | -5.21% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $375 → $350 | $438.85 | -20.25% | 10 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $11.12 | -10.07% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $34.02 | +305.64% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $2.06 | +288.35% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $296.09 | +28.34% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $139.00 | +57.55% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $4.40 | +172.73% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $5.15 | +249.51% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.87 | +1,052.21% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $78.06 | +21.70% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $1.73 | +1,345.09% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $72 → $75 | $71.40 | +5.04% | 3 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $1.74 | +417.24% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | n/a | $14.83 | - | 6 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,200 → $500 | $1.99 | +24,994.10% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $11.38 | +84.53% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.99 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $17.52 | +379.45% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.07 | - | 3 | Jul 11, 2017 |
Immuneering
Sep 25, 2025
Maintains: Outperform
Price Target: $21 → $30
Current: $6.40
Upside: +368.75%
Bicycle Therapeutics
Aug 11, 2025
Maintains: Outperform
Price Target: $48 → $44
Current: $8.36
Upside: +426.63%
Mind Medicine (MindMed)
Aug 4, 2025
Reinstates: Outperform
Price Target: $25
Current: $12.62
Upside: +98.10%
Atai Life Sciences
Jul 29, 2025
Initiates: Outperform
Price Target: $14
Current: $5.54
Upside: +152.71%
Praxis Precision Medicines
Jul 8, 2025
Maintains: Outperform
Price Target: $97 → $115
Current: $54.43
Upside: +111.28%
ACADIA Pharmaceuticals
Jun 26, 2025
Maintains: Perform
Price Target: $19 → $22
Current: $21.51
Upside: +2.30%
Prothena Corporation
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $10.38
Upside: -
Tvardi Therapeutics
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $39.72
Upside: +63.65%
Jasper Therapeutics
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $2.36
Upside: +2,660.08%
Inovio Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $2.66
Upside: +388.72%
May 8, 2025
Maintains: Outperform
Price Target: $70 → $75
Current: $49.20
Upside: +52.44%
Mar 14, 2025
Upgrades: Outperform
Price Target: $90
Current: $58.04
Upside: +55.07%
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $15.96
Upside: +163.16%
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $39.14
Upside: -15.69%
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $25.18
Upside: +58.86%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $3.01
Upside: +564.45%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $7.48
Upside: +301.07%
Dec 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $8.31
Upside: +140.67%
Oct 31, 2024
Maintains: Outperform
Price Target: $270 → $255
Current: $151.61
Upside: +68.19%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $86.51
Upside: -5.21%
Oct 23, 2024
Maintains: Outperform
Price Target: $375 → $350
Current: $438.85
Upside: -20.25%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $11.12
Upside: -10.07%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $34.02
Upside: +305.64%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $2.06
Upside: +288.35%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $296.09
Upside: +28.34%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $139.00
Upside: +57.55%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $4.40
Upside: +172.73%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $5.15
Upside: +249.51%
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $0.87
Upside: +1,052.21%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $78.06
Upside: +21.70%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $1.73
Upside: +1,345.09%
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $71.40
Upside: +5.04%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $1.74
Upside: +417.24%
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $14.83
Upside: -
Nov 30, 2023
Maintains: Outperform
Price Target: $1,200 → $500
Current: $1.99
Upside: +24,994.10%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $11.38
Upside: +84.53%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.99
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $17.52
Upside: +379.45%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.07
Upside: -